WO2000009107A3 - Sulfonamides of n-containing heterocyclic thioesters for vision and memory disorders - Google Patents

Sulfonamides of n-containing heterocyclic thioesters for vision and memory disorders Download PDF

Info

Publication number
WO2000009107A3
WO2000009107A3 PCT/US1999/018240 US9918240W WO0009107A3 WO 2000009107 A3 WO2000009107 A3 WO 2000009107A3 US 9918240 W US9918240 W US 9918240W WO 0009107 A3 WO0009107 A3 WO 0009107A3
Authority
WO
WIPO (PCT)
Prior art keywords
vision
sulfonamides
containing heterocyclic
memory disorders
heterocyclic thioesters
Prior art date
Application number
PCT/US1999/018240
Other languages
French (fr)
Other versions
WO2000009107A2 (en
Inventor
Douglas T Ross
Hansjorg Sauer
Gregory S Hamilton
Joseph P Steiner
Original Assignee
Guilford Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guilford Pharm Inc filed Critical Guilford Pharm Inc
Priority to JP2000564610A priority Critical patent/JP2002522483A/en
Priority to AU55555/99A priority patent/AU5555599A/en
Priority to CA002336148A priority patent/CA2336148A1/en
Priority to MXPA00013033A priority patent/MXPA00013033A/en
Priority to EP99942107A priority patent/EP1105126A2/en
Publication of WO2000009107A2 publication Critical patent/WO2000009107A2/en
Publication of WO2000009107A3 publication Critical patent/WO2000009107A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

This invention relates to pharmaceutical compositions and methods for treating a vision disorder, improving vision, treating memory impairment, or enhancing memory performance using N-linked sulfonamides of heterocyclic thioesters. 3-(para-Methoxyphenyl) -1-propylmercaptyl (2S)-N-(benzenesulfonyl)pyrrolidine-2-carboxylate; 3-(para-Methoxyphenyl)-1-propylmercaptyl (2S)-N-(-toluenesulfonyl)pyrrolidine-2-carboxylate, and 1,5-Diphenyl-3-pentylmercaptyl N-(paratoluenesulfonyl)pipecolate are specifically claimed.
PCT/US1999/018240 1998-08-14 1999-08-12 Sulfonamides of n-containing heterocyclic thioesters for vision and memory disorders WO2000009107A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2000564610A JP2002522483A (en) 1998-08-14 1999-08-12 N-linked sulfonamides of heterocyclic thioesters for visual and memory impairments
AU55555/99A AU5555599A (en) 1998-08-14 1999-08-12 N-linked sulfonamide of heterocyclic thioesters for vision and memory disorders
CA002336148A CA2336148A1 (en) 1998-08-14 1999-08-12 Sulfonamides of n-containing heterocyclic thioesters for vision and memory disorders
MXPA00013033A MXPA00013033A (en) 1998-08-14 1999-08-12 N-linked sulfonamide of heterocyclic thioesters for vision and memory disorders.
EP99942107A EP1105126A2 (en) 1998-08-14 1999-08-12 Sulfonamides of n-containing heterocyclic thioesters for vision and memory disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/134,421 1998-08-14
US09/134,421 US7410995B1 (en) 1998-08-14 1998-08-14 N-linked sulfonamide of heterocyclic thioesters for vision and memory disorders

Publications (2)

Publication Number Publication Date
WO2000009107A2 WO2000009107A2 (en) 2000-02-24
WO2000009107A3 true WO2000009107A3 (en) 2000-06-15

Family

ID=22463326

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/018240 WO2000009107A2 (en) 1998-08-14 1999-08-12 Sulfonamides of n-containing heterocyclic thioesters for vision and memory disorders

Country Status (7)

Country Link
US (1) US7410995B1 (en)
EP (1) EP1105126A2 (en)
JP (1) JP2002522483A (en)
AU (1) AU5555599A (en)
CA (1) CA2336148A1 (en)
MX (1) MXPA00013033A (en)
WO (1) WO2000009107A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1341779B1 (en) 2000-12-13 2006-06-21 Wyeth Heterocyclic sulfonamide inhibitors of beta amyloid production
US6657070B2 (en) 2000-12-13 2003-12-02 Wyeth Production of chirally pure α-amino acids and N-sulfonyl α-amino acids
AUPS160602A0 (en) * 2002-04-08 2002-05-16 University Of Queensland, The Therapeutic method
AU2002952086A0 (en) * 2002-10-16 2002-11-07 The University Of Queensland Treatment of osteoarthritis
CN1780829B (en) 2003-03-31 2010-12-29 惠氏公司 Fluoro- and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof
JP5451611B2 (en) 2007-07-26 2014-03-26 ヴァイティー ファーマシューティカルズ，インコーポレイテッド Cyclic inhibitor of 11β-hydroxysteroid dehydrogenase 1
AR069207A1 (en) 2007-11-07 2010-01-06 Vitae Pharmaceuticals Inc CYCLIC UREAS AS INHIBITORS OF THE 11 BETA - HIDROXI-ESTEROIDE DESHIDROGENASA 1
US8440658B2 (en) 2007-12-11 2013-05-14 Vitae Pharmaceuticals, Inc. Cyclic urea inhibitors of 11β-hydroxysteroid dehydrogenase 1
TW200934490A (en) 2008-01-07 2009-08-16 Vitae Pharmaceuticals Inc Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1
EP2254872A2 (en) 2008-02-15 2010-12-01 Vitae Pharmaceuticals, Inc. Cycloalkyl lactame derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
TW200944526A (en) * 2008-04-22 2009-11-01 Vitae Pharmaceuticals Inc Carbamate and urea inhibitors of 11β-hydroxysteroid dehydrogenase 1
RU2531272C2 (en) 2008-05-01 2014-10-20 Вайтаи Фармасьютиклз, Инк. Cyclic inhibitors of 11beta-hydroxysteroid-dehydrogenase 1
EP2324018B1 (en) 2008-07-25 2013-09-04 Boehringer Ingelheim International GmbH Cyclic inhibitors of 11 beta-hydroxysteroid dehydrogenase 1
JP5777030B2 (en) 2008-07-25 2015-09-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Inhibitor of 11β-hydroxysteroid dehydrogenase 1
US8487094B2 (en) 2008-07-25 2013-07-16 Boehringer Ingelheim International Gmbh Synthesis of inhibitors of 11β-hydroxysteroid dehydrogenase type 1
DE102008060549A1 (en) 2008-12-04 2010-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Drug-peptide construct for extracellular accumulation
US8637505B2 (en) 2009-02-04 2014-01-28 Boehringer Ingelheim International Gmbh Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
UA109255C2 (en) 2009-04-30 2015-08-10 Берінгер Інгельхайм Інтернешнл Гмбх Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8927539B2 (en) 2009-06-11 2015-01-06 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 based on the 1,3-oxazinan-2-one structure
US8552212B2 (en) 2009-11-05 2013-10-08 Boehringer Ingelheim International Gmbh Chiral phosphorus ligands
EP2576570A1 (en) 2010-05-26 2013-04-10 Boehringer Ingelheim International GmbH 2-oxo-1,2-dihydropyridin-4-ylboronic acid derivatives
US8933072B2 (en) 2010-06-16 2015-01-13 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
EP2585444B1 (en) 2010-06-25 2014-10-22 Boehringer Ingelheim International GmbH Azaspirohexanones as inhibitors of 11-beta-hsd1 for the treatment of metabolic disorders
EP2635268A1 (en) 2010-11-02 2013-09-11 Boehringer Ingelheim International GmbH Pharmaceutical combinations for the treatment of metabolic disorders
WO2023178378A1 (en) * 2022-03-21 2023-09-28 DMTC Limited Mip inhibitors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998029116A1 (en) * 1996-12-31 1998-07-09 Guilford Pharmaceuticals Inc. N-linked sulfonamides of heterocyclic thioesters
WO1998055090A1 (en) * 1997-06-04 1998-12-10 Guilford Pharmaceuticals Inc. Hair growth compositions and uses
WO1999014998A2 (en) * 1997-09-24 1999-04-01 Amgen Inc. Method for preventing and treating hearing loss using sensorineurotrophic compounds
WO1999062489A1 (en) * 1998-06-03 1999-12-09 Gpi Nil Holdings, Inc. N-linked sulfonamide of heterocyclic thioester hair growth compounds and uses

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839342A (en) 1987-09-03 1989-06-13 University Of Georgia Research Foundation, Inc. Method of increasing tear production by topical administration of cyclosporin
EP0356399A3 (en) 1988-08-26 1991-03-20 Sandoz Ag Substituted 4-azatricyclo (22.3.1.04.9) octacos-18-ene derivatives, their preparation and pharmaceutical compositions containing them
US5166317A (en) 1988-10-31 1992-11-24 Houston Biotechnology Incorporated Neurotrophic factor
US5284826A (en) 1989-07-24 1994-02-08 Sandoz Ltd. 0-hydroxyethyl and acyloxyethyl derivatives of [ser]8 cyclosporins
US5244902A (en) 1989-08-21 1993-09-14 Beth Israel Hospital Association Topical application of spiperone or derivatives thereof for treatment of pathological conditions associated with immune responses
US5667968A (en) 1989-08-30 1997-09-16 Regeneron Pharmaceuticals, Inc. Prevention of retinal injury and degeneration by specific factors
US5252319A (en) 1990-06-12 1993-10-12 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5192773A (en) 1990-07-02 1993-03-09 Vertex Pharmaceuticals, Inc. Immunosuppressive compounds
CA2054983A1 (en) 1990-11-08 1992-05-09 Sotoo Asakura Suspendible composition and process for preparing the same
DK0581959T3 (en) 1991-04-26 2001-01-29 Fujisawa Pharmaceutical Co Use of macrolide compounds for eye diseases
US5565560A (en) 1991-05-13 1996-10-15 Merck & Co., Inc. O-Aryl,O-alkyl,O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
ZA924953B (en) 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
US5189042A (en) 1991-08-22 1993-02-23 Merck & Co. Inc. Fluoromacrolides having immunosuppressive activity
US5457111A (en) 1991-09-05 1995-10-10 Abbott Laboratories Macrocyclic immunomodulators
US5194434A (en) 1991-12-03 1993-03-16 Texas A&M University System Use of OB-101 to treat ocular inflammation
US5198454A (en) 1991-12-03 1993-03-30 Texas A&M University System Use of OB-104 to treat ocular inflammation
US5688765A (en) 1992-04-21 1997-11-18 The Schepens Eye Research Institute, Inc. Ocular therapy in Sjogren's syndrome using topically applied androgensor TGF-β
JPH07508716A (en) 1992-04-21 1995-09-28 ザ　スキーペンズ　アイ　リサーチ　インスティテュート，インコーポレイテッド Ocular androgen therapy in Sjogren's syndrome
CA2106034A1 (en) 1992-09-24 1994-03-25 Ralph J. Russo 21-norrapamycin
US5258389A (en) 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
US5693645A (en) 1992-12-23 1997-12-02 Beth Israel Deaconess Medical Center, Inc. Use of spiperone or spiperone derivatives as immunosuppressant agents
WO1995003009A1 (en) 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Method of treatment of macular degeneration
US5700909A (en) 1993-07-30 1997-12-23 The Regents Of The University Of California Prosaposin and cytokine-derived peptides
US5468752A (en) 1994-04-04 1995-11-21 Freeman; William R. Treatment of conditions of abnormally increased intraocular pressure by administration of HPMPC and related phosphonylmethoxyalkylcytosines
US5527533A (en) 1994-10-27 1996-06-18 Board Of Trustees Of The University Of Illinois Method of retarding and ameliorating central nervous system and eye damage
US5641750A (en) 1995-11-29 1997-06-24 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
US5641749A (en) 1995-11-29 1997-06-24 Amgen Inc. Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
AU1743997A (en) 1996-12-20 1998-07-17 Geron Corporation Poly(adp-ribose) polymerase inhibitors to treat diseases associated with cellular senescence

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998029116A1 (en) * 1996-12-31 1998-07-09 Guilford Pharmaceuticals Inc. N-linked sulfonamides of heterocyclic thioesters
WO1998055090A1 (en) * 1997-06-04 1998-12-10 Guilford Pharmaceuticals Inc. Hair growth compositions and uses
WO1999014998A2 (en) * 1997-09-24 1999-04-01 Amgen Inc. Method for preventing and treating hearing loss using sensorineurotrophic compounds
WO1999062489A1 (en) * 1998-06-03 1999-12-09 Gpi Nil Holdings, Inc. N-linked sulfonamide of heterocyclic thioester hair growth compounds and uses

Also Published As

Publication number Publication date
AU5555599A (en) 2000-03-06
CA2336148A1 (en) 2000-02-24
JP2002522483A (en) 2002-07-23
EP1105126A2 (en) 2001-06-13
MXPA00013033A (en) 2002-04-24
WO2000009107A2 (en) 2000-02-24
US7410995B1 (en) 2008-08-12

Similar Documents

Publication Publication Date Title
WO2000009107A3 (en) Sulfonamides of n-containing heterocyclic thioesters for vision and memory disorders
NO20033732L (en) N-substituted non-aryl heterocyclic NMDA / NR2B antagonists, and pharmaceutical compositions comprising such compounds.
WO2002085909A8 (en) 9-deazaguanine derivatives as inhibitors of gsk-3
WO2000043395A8 (en) Substituted porphyrins
BR9917038A (en) Compound, pharmaceutical composition, method of modulating chemokine receptor activity, method of treatment or prevention of inflammatory diseases, method of treatment or prevention of asthma and method of treatment or prevention of inflammatory disorders
WO2000008015A3 (en) Fsh mimetics for the treatment of infertility
WO2003037271A3 (en) Compounds, pharmaceutical compositions and methods of use therefor
IL161829A (en) 1,2,4 - thiadiazole derivatives, some of which are novel and pharmaceutical compositions comprising the same for treating disorders mediated by melanocortin receptor modulators
ATE284670T1 (en) COMBINATION OF ACID PROTEASE ENZYMES AND ACID BUFFERS AND USE THEREOF
BR9811099A (en) Urokinase inhibitors
WO1999024051A3 (en) Application of vasopressin antagonists for treating disturbances or illnesses of the inner ear
ATE202706T1 (en) USE OF 9-DEOXYPROSTAGLAND INDERIVATIVES FOR THE TREATMENT OF GLAUCOMA
CA2348735A1 (en) Heterocyclic potassium channel inhibitors
UA66865C2 (en) Indenopyrrolocarbazoles, pharmaceutical composition, method for inhibiting kinase activity and method for treatment (variants)
CA2276429A1 (en) Compositions for the treatment of ards or irds containing 3-(cyclopropylmethoxy)-n-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)benzamide and lung surfactant
WO2000006083A3 (en) Sulfonamide derivatives
WO1998039293A3 (en) 13-thia prostaglandins for use in glaucoma therapy
WO2001004116A3 (en) Neurotrophic pyrrolidines and piperidines, and related compositions containing them
WO2000009112A3 (en) Heterocyclic esters or amides for vision and memory disorders
BR9914848A (en) Composition and process for the treatment of disorders of the external retina
CA2094806A1 (en) Aminosulfonyl urea acat inhibitors
CA2179264A1 (en) 6-(2-Imidazolinylamino)Quinoline Compounds Useful as Alpha-2 Adrenoceptor Agonists
WO2002014275A3 (en) Heterocyclic sulfonamide derivatives and their use for potentiating glutamate receptor function
WO2002014294A3 (en) Heterocyclic sulfonamide derivatives and their use for potentiating glutamate receptor function
WO2004007441A3 (en) Novel derivatives of 4,4'-dithiobis-(3-aminobutane-1-sulphonates) and compositions containing same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/013033

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 55555/99

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2336148

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 564610

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999942107

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1999942107

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999942107

Country of ref document: EP